WallStreetZenWallStreetZen

NASDAQ: OBIO
Orchestra Biomed Holdings Inc Stock

$5.27-0.04 (-0.75%)
Updated Mar 28, 2024
OBIO Price
$5.27
Fair Value Price
$0.01
Market Cap
$188.55M
52 Week Low
$4.26
52 Week High
$23.39
P/E
-3.56x
P/B
2.77x
P/S
109.91x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.76M
Earnings
-$49.12M
Gross Margin
93.3%
Operating Margin
-1,779.71%
Profit Margin
-1,779.7%
Debt to Equity
0.4
Operating Cash Flow
-$46M
Beta
0.46
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

OBIO Overview

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

Zen Score

–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how OBIO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

OBIO ($5.27) is overvalued by 49,319.74% relative to our estimate of its Fair Value price of $0.01 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
OBIO ($5.27) is not significantly undervalued (49,319.74%) relative to our estimate of its Fair Value price of $0.01 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
OBIO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more OBIO due diligence checks available for Premium users.

Be the first to know about important OBIO news, forecast changes, insider trades & much more!

OBIO News

Valuation

OBIO fair value

Fair Value of OBIO stock based on Discounted Cash Flow (DCF)
Price
$5.27
Fair Value
$0.01
Overvalued by
49,319.74%
OBIO ($5.27) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
OBIO ($5.27) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
OBIO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

OBIO price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-3.56x
Industry
14.26x
Market
44.51x

OBIO price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.77x
Industry
6.21x
OBIO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

OBIO's financial health

Profit margin

Revenue
$262.0k
Net Income
-$12.8M
Profit Margin
-4,892.4%
OBIO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
OBIO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$95.2M
Liabilities
$27.2M
Debt to equity
0.4
OBIO's short-term assets ($89.11M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OBIO's short-term assets ($89.11M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OBIO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$11.0M
Investing
$33.2M
Financing
-$10.7M
OBIO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

OBIO vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
OBIO$188.55M-0.66%-3.56x2.77x
RGLS$188.54M0.00%-1.82x8.90x
PRQR$186.30M-3.78%-6.03x4.14x
LENZ$185.78M+2.38%-1.46x1.01x
AMLX$192.50M-1.39%3.89x0.44x

Orchestra Biomed Holdings Stock FAQ

What is Orchestra Biomed Holdings's quote symbol?

(NASDAQ: OBIO) Orchestra Biomed Holdings trades on the NASDAQ under the ticker symbol OBIO. Orchestra Biomed Holdings stock quotes can also be displayed as NASDAQ: OBIO.

If you're new to stock investing, here's how to buy Orchestra Biomed Holdings stock.

What is the 52 week high and low for Orchestra Biomed Holdings (NASDAQ: OBIO)?

(NASDAQ: OBIO) Orchestra Biomed Holdings's 52-week high was $23.39, and its 52-week low was $4.26. It is currently -77.47% from its 52-week high and 23.85% from its 52-week low.

How much is Orchestra Biomed Holdings stock worth today?

(NASDAQ: OBIO) Orchestra Biomed Holdings currently has 35,777,412 outstanding shares. With Orchestra Biomed Holdings stock trading at $5.27 per share, the total value of Orchestra Biomed Holdings stock (market capitalization) is $188.55M.

Orchestra Biomed Holdings stock was originally listed at a price of $11.26 in Aug 13, 2020. If you had invested in Orchestra Biomed Holdings stock at $11.26, your return over the last 3 years would have been -53.2%, for an annualized return of -22.36% (not including any dividends or dividend reinvestments).

How much is Orchestra Biomed Holdings's stock price per share?

(NASDAQ: OBIO) Orchestra Biomed Holdings stock price per share is $5.27 today (as of Mar 28, 2024).

What is Orchestra Biomed Holdings's Market Cap?

(NASDAQ: OBIO) Orchestra Biomed Holdings's market cap is $188.55M, as of Mar 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Orchestra Biomed Holdings's market cap is calculated by multiplying OBIO's current stock price of $5.27 by OBIO's total outstanding shares of 35,777,412.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.